Patents by Inventor Yik Teng WONG
Yik Teng WONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11523988Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.Type: GrantFiled: November 26, 2019Date of Patent: December 13, 2022Assignees: Catalent U.K. Swindon Zydis Limited, Mymetics CorporationInventors: Yik Teng Wong, Charli Smardon, Khojasteh Shirkhani, Mario Amacker, Sylvain Fleury, Antonius Johannes Hendrikus Stegmann
-
Patent number: 11517533Abstract: Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.Type: GrantFiled: October 25, 2017Date of Patent: December 6, 2022Assignee: Catalent U.K. Swindon Zydis LimitedInventors: Leon Paul Grother, Keiko Tsutsumi, Rosaleen Theresa McLaughlin, Yik Teng Wong
-
Patent number: 11224571Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.Type: GrantFiled: August 23, 2021Date of Patent: January 18, 2022Assignees: Catalent U.K. Swindon Zydis Limited, Mymetics CorporationInventors: Yik Teng Wong, Charli Smardon, Khojasteh Shirkhani, Mario Amacker, Sylvain Fleury, Antonius Johannes Hendrikus Stegmann
-
Publication number: 20210386660Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.Type: ApplicationFiled: August 23, 2021Publication date: December 16, 2021Applicants: Catalent U.K. Swindon Zydis Limited, Mymetics CorporationInventors: Yik Teng WONG, Charli SMARDON, Khojasteh SHIRKHANI, Mario AMACKER, Sylvain FLEURY, Antonius Johannes Hendrikus STEGMANN
-
Publication number: 20210207003Abstract: The present disclosure is directed to processes for reducing the endotoxin level in gelatin and the resulting gelatin with low endotoxin content. The process includes dissolving a salt in a gelatin solution and filtering the gelatin-salt solution using anion exchange to reduce the endotoxin level. After reducing the endotoxin level of the gelatin-salt solution, the low endotoxin gelatin-salt solution is desalted to remove the salt, thereby producing a low endotoxin gelatin solution.Type: ApplicationFiled: March 24, 2021Publication date: July 8, 2021Applicant: Catalent U.K. Swindon Zydis LimitedInventors: Yik Teng WONG, Khojasteh SHIRKHANI, Ami POWE, Sarah STEWART, Charli SMARDON
-
Patent number: 11026883Abstract: Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.Type: GrantFiled: October 13, 2017Date of Patent: June 8, 2021Assignee: Catalent U.K. Swindon Zydis LimitedInventors: Emilie Masto, Lisa Garrett, Niamh Barrat, Yik Teng Wong, Rosaleen Theresa McLaughlin, Susan Gerrard Banbury
-
Patent number: 10988638Abstract: The present disclosure is directed to processes for reducing the endotoxin level in gelatin and the resulting gelatin with low endotoxin content. The process includes dissolving a salt in a gelatin solution and filtering the gelatin-salt solution using anion exchange to reduce the endotoxin level. After reducing the endotoxin level of the gelatin-salt solution, the low endotoxin gelatin-salt solution is desalted to remove the salt, thereby producing a low endotoxin gelatin solution.Type: GrantFiled: March 7, 2019Date of Patent: April 27, 2021Assignee: Catalent U.K. Swindon Zydis LimitedInventors: Yik Teng Wong, Khojasteh Shirkhani, Ami Powe, Sarah Stewart, Charli Smardon
-
Publication number: 20200170933Abstract: The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) harboring an immunogenic amount of at least one vaccinal target molecule, with or without adjuvant. Specifically, Applicants discovered a combination of the composition of the liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and the manufacturing conditions for the dosage forms that can produce a freeze dried sublingual dosage form having physical robustness, particle and antigen integrity and stability.Type: ApplicationFiled: November 26, 2019Publication date: June 4, 2020Applicants: Catalent U.K. Swindon Zydis Limited, Mymetics CorporationInventors: Yik Teng WONG, Charli SMARDON, Khojasteh SHIRKHANI, Mario AMACKER, Sylvain FLEURY, Antonius Johannes Henrikus STEGMANN
-
Publication number: 20200138721Abstract: Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.Type: ApplicationFiled: October 25, 2017Publication date: May 7, 2020Applicant: Catalent U.K. Swindon Zydis LimitedInventors: Leon Paul GROTHER, Keiko TSUTSUMI, Rosaleen Theresa MCLAUGHLIN, Yik Teng WONG
-
Publication number: 20190314274Abstract: Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.Type: ApplicationFiled: October 13, 2017Publication date: October 17, 2019Applicant: Catalent U.K. Swindon Zydis LimitedInventors: Emilie MASTO, Lisa GARRETT, Niamh BARRAT, Yik Teng WONG, Rosaleen Theresa MCLAUGHLIN, Susan Gerrard BANBURY
-
Publication number: 20190276707Abstract: The present disclosure is directed to processes for reducing the endotoxin level in gelatin and the resulting gelatin with low endotoxin content. The process includes dissolving a salt in a gelatin solution and filtering the gelatin-salt solution using anion exchange to reduce the endotoxin level. After reducing the endotoxin level of the gelatin-salt solution, the low endotoxin gelatin-salt solution is desalted to remove the salt, thereby producing a low endotoxin gelatin solution.Type: ApplicationFiled: March 7, 2019Publication date: September 12, 2019Applicant: Catalent U.K. Swindon Zydis LimitedInventors: Yik Teng WONG, Khojasteh SHIRKHANI, Ami HITCHING, Sarah STEWART
-
Publication number: 20160324767Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: July 6, 2016Publication date: November 10, 2016Applicants: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 9415015Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: April 4, 2008Date of Patent: August 16, 2016Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 9408805Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: May 27, 2014Date of Patent: August 9, 2016Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Publication number: 20140271722Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: May 27, 2014Publication date: September 18, 2014Applicants: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 8329196Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: April 4, 2008Date of Patent: December 11, 2012Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette R. Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 7972621Abstract: The invention disclosed herein relates to a pharmaceutical composition comprising a carrier and an active ingredient, wherein the carrier is at least one fish gelatin predetermined on the basis of the molecular weight profile of the gelatin. In some embodiments, particularly when the concentration of carrier comprises a relatively lower percentage of the total composition, the carrier may be exclusively a high molecular weight fish gelatin, or may be comprised of a mixture with standard molecular weight gelatin in which high molecular weight gelatin comprises a predominant portion. In those embodiments where the concentration of carrier comprises a relatively larger percentage of the total composition, the carrier may be an exclusively standard molecular weight fish gelatin, or may be comprised of a mixture in which standard molecular weight gelatin comprises a predominant portion. Thus, compositions may be designed to optimize performance for various required gelatin concentration formulations.Type: GrantFiled: June 3, 2004Date of Patent: July 5, 2011Assignee: R.P. Scherer Technologies, LLCInventors: Desmond Yik Teng Wong, Leon Paul Grother, Andrzej Jan Brzozowski
-
Publication number: 20080193535Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: April 4, 2008Publication date: August 14, 2008Applicant: Alk-Abello A/SInventors: Henrik Hugo Jacobi, Annette R. Lundegaard, Christian G. Houghton, Stig Aasmul-Olsen, Lise L. Maerkedahl, Jan S. Andersen, Kerry Mallindin, Owen J. Murray, Susan G. Banbury, Desmond Yik Teng Wong, Lisa M. Garrett, Michael Hall
-
Publication number: 20080187558Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: April 4, 2008Publication date: August 7, 2008Applicant: ALK-Abello A/SInventors: Henrik H. Jacobi, Annette R. Lundegaard, Christain G. Houghton, Stig Aasmul-Olsen, Lise L. Maerkedahl, Jan S. Andersen, Kerry Mallindine, Owen J. Murray, Susan G. Banbury, Desmond Yik Teng Wong, Lisa M. Garrett, Michael Hall
-
Publication number: 20040166123Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: November 26, 2003Publication date: August 26, 2004Inventors: Henrik H. Jacobi, Annette R. Lundegaard, Christian G. Houghton, Stig Aasmul-Olsen, Lise L. Maerkedahl, Jan S. Andersen, Kerry Mallindine, Owen J. Murray, Susan G Banbury, Desmond Yik Teng Wong, Lisa M. Garrett, Michael Hall